IMUX Earnings Prediction
The chart below shows how IMUX performed 10 days before and after its earnings report, based on data from the past quarters. Typically, IMUX sees a +53.96% change in stock price 10 days leading up to the earnings, and a +2.47% change 10 days following the report. On the earnings day itself, the stock moves by +2.95%. This data can give you a slight idea of what to expect for the next quarter's release.
IMUX Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
--
--
--
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
-0.24
-52.94%
14.29%
No Data Available
IMUX Earnings Analysis
Immunic, Inc. Common Stock Corporation (IMUX.O) Earnings Conference Call
Positive
Cash Reserves Outlook: In the third quarter of 2024, Immunic ended with $59.1 million in cash and cash equivalents, which is expected to fund operations into the third quarter of 2025.
R&D Expense Increase: R&D expenses increased to $21.4 million for the three months ended September 30, 2024, compared to $19.8 million for the same period in 2023, driven by external development costs related to clinical trials.
R&D Expense Decrease: R&D expenses for the nine months ended September 30, 2024, were $58.4 million, a decrease from $63.9 million for the same period in 2023, primarily due to the prioritization of the izunmab program.
G&A Expense Increase: G&A expenses increased to $4.4 million for the three months ended September 30, 2024, compared to $3.8 million for the same period in 2023, primarily related to personnel expenses.
G&A Expense Increase: G&A expenses for the nine months ended September 30, 2024, were $14 million, compared to $11.9 million for the same period in 2023, reflecting increased personnel and legal expenses.
Negative
R&D Expense Increase: R&D expenses increased to $21.4 million for the three months ended September 30, 2024, compared to $19.8 million for the same period ended September 30, 2023, indicating rising costs.
G&A Expense Increase: G&A expenses rose to $4.4 million for the three months ended September 30, 2024, up from $3.8 million for the same period in 2023, reflecting increased operational costs.
Net Loss Comparison: Net loss for the three months ended September 30, 2024, was approximately $24.4 million, compared to a net loss of approximately $22.8 million for the same period in 2023, showing worsening financial performance.
Net Loss Comparison: The net loss for the nine months ended September 30, 2024, was approximately $75.3 million, compared to a net loss of approximately $72 million for the same period in 2023, indicating a continued decline in profitability.
R&D Expense Decrease: R&D expenses for the nine months ended September 30, 2024, were $58.4 million compared to $63.9 million for the same period in 2023, suggesting a decrease in investment despite ongoing projects.
IMUX FAQs
How does IMUX typically perform around its earnings report dates?
Is Immunic, Inc. (IMUX) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
IMUX Earning Call Sentiment
Immunic, Inc. (IMUX) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
IMUX.O
0.92%Positive
The earnings call summary indicates financial challenges with ongoing net losses and increased expenses, despite having cash to fund operations into Q3 2025. There are competitive and supply chain risks, and a lack of shareholder return plans. The Q&A reveals management's unclear responses and inability to provide guidance, raising uncertainty. While there is interest in partnerships, no specific details were provided. Overall, these factors suggest a negative sentiment, likely leading to a stock price decline in the range of -2% to -8% over the next two weeks.